Lates News

According to AI Fast News, Huatai Securities released a research report on January 18th, giving a "buy" rating to Zhongsheng Pharmaceutical (002317.SZ). The reasons for the rating include: 1) The domestic commercialization cooperation of the long-acting GLP-1RAY1225 has been achieved, and continued attention to overseas equity authorization; 2) The listing of the innovative flu drug Arlovidine tablets, and expectations for gradual increase in sales volume. (Daily Economic News)